DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Ovarian Cancer
  4. Research Highlights/News
  5. 2018 Ovarian Cancer Research Program

Ovarian Cancer

NEWS RELEASE

Released: February 13, 2018

Defense Health Program
Department of Defense Ovarian Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)

Although funds have not been appropriated for the FY18 Department of Defense Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

FY18 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2018. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of federal funds appropriated for the OCRP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease.


Award Mechanism PI Eligibility Key Mechanism Elements Funding
Clinical Development Award Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
  • Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.
  • Near-term impact is expected.
  • Preclinical studies in animals are not allowed.
  • Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.
  • Preliminary data are required.
  • Optional Nested Early-Career Investigator (ECI): Applications proposing clinical trials and having an ECI that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Maximum funding of $600,000 for direct costs (plus indirect costs)
  • With ECI option the maximum funding is $800,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
Omics Consortium Development Award Must be an independent investigator at the Associate Professor level or above (or equivalent).
  • Supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the origin of ovarian cancer, with an emphasis on risk stratification, screening and early detection.
  • Funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.
  • Ovarian cancer advocate(s) are required on the research team.
  • Funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in FY20, pending availability of funds.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Maximum funding of $400,000 for direct costs (plus indirect costs)
  • Period of performance not to exceed 2 years
Investigator-Initiated Research Award Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
  • Supports meritorious basic and clinically oriented research in ovarian cancer.
  • Impact is an important review criterion.
  • Preliminary data are required.
  • Clinical trials are not allowed.
  • Pre-application is required; application is by invitation only.
  • Maximum funding of $450,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
Ovarian Cancer Academy Award - Early-Career Investigator Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline. A letter attesting to eligibility is required.
  • Supports the addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
  • ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
  • A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
  • A Designated Mentor may only mentor one ECI candidate.
  • The Designated Mentor is not required to be at the same institution as the ECI.
  • Preliminary data are required.
  • Clinical trials are allowed.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Maximum funding of $725,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
Pilot Award Investigators at or above the postdoctoral level (or equivalent).
  • Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
  • Innovation and Impact are important review criteria.
  • Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.
  • Clinical trials are not allowed.
  • Pre-application is required and blinded; application submission is by invitation only.
  • Maximum funding of $250,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Monday, December 16, 2024